Other Events ·
Nasdaq notifies company of delisting following Chapter 11 bankruptcy filing; trading suspends Nov. 11
KPTIKaryopharm Therapeutics Inc.
The Nasdaq Stock Market notified Karyopharm Therapeutics Inc. that its common stock will be delisted from the Nasdaq Global Select Market due to the company's voluntary Chapter 11 bankruptcy petitions filed on November 2, 2026. Trading of the shares is scheduled to suspend at the opening of business on November 11, 2026, after which they are expected to begin trading on an over-the-counter market under the symbol KPTIQ. The company stated it will not appeal the delisting determination and warned that existing equity securities are expected to have no value, resulting in a complete loss for current shareholders under the proposed reorganization plan. Karyopharm Therapeutics Inc. operates as a biopharmaceutical company focused on developing therapies for cancer.